TL;DR
This study provides a comprehensive pan-cancer analysis of Mono-ADP-ribosyltransferases-1 (ART1), revealing its complex role in various cancers, its association with patient prognosis, and its significant involvement in the tumor immune microenvironment. The findings highlight ART1 as a potential therapeutic target, particularly in gastric cancer, for developing novel immunotherapies.
What Problem Does This Paper Address?
Cancer remains a major global health challenge, with gastric cancer (GC) being particularly insidious due to late diagnosis and poor survival rates. While advancements in immunotherapy have transformed cancer treatment, patient responses are highly variable, necessitating the identification of robust biomarkers for prognosis and therapeutic targeting. The specific role of ART1, a mono-ADP-ribosylase, in the broad landscape of cancer, especially in GC, and its intricate relationship with the tumor microenvironment (TME) and immune responses were largely unexplored. This paper aims to fill this knowledge gap by conducting a comprehensive pan-cancer analysis of ART1's expression, prognostic value, and its interplay with key factors like tumor stemness, RNA modifications, and immune cell infiltration.
Methods
The researchers employed a multi-pronged approach:
- Bioinformatics Analysis: They meticulously curated genomic, transcriptomic, and clinical data from The Cancer Genome Atlas (TCGA) and Genotypic Tissue Expression (GTEx) repositories, covering 41 cancer types. This involved:
- Differential Expression Analysis: Comparing ART1 mRNA and protein levels between tumor and normal tissues.
- Prognostic Value Assessment: Using univariate Cox regression and Kaplan-Meier survival analysis to evaluate ART1's association with overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI).
- Immune Role Identification: Analyzing ART1's correlation with immune regulatory genes, immune checkpoint genes, and immune cell infiltration using databases like TISMO, TIMER, and CIBERSORT.
- Mutation Landscape Analysis: Investigating ART1's genetic alterations using cBioPortal.
- RNA Modification Gene Correlation: Examining the relationship between ART1 expression and genes involved in m1A, m5C, and m6A RNA modifications.
- Tumor Stemness Correlation: Assessing ART1's association with various tumor stemness indices.
- Functional Enrichment Analysis: Using STRING database, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) to identify pathways and biological processes influenced by ART1.
- Bayesian Co-localization Analysis: Employing the "coloc" R package to investigate potential genetic overlap between ART1 and digestive tract tumors (STAD and CRC) using GWAS data.
- Experimental Validation: To corroborate their findings, they conducted in vitro experiments using gastric cancer cell lines (HGC-27, MKN-45, AGS) and normal gastric epithelial cells (GSE). This included:
- Quantitative Real-Time PCR (qRT-PCR): To measure ART1 mRNA expression.
- Western Blot: To assess ART1 protein levels.
- Flow Cytometry: To evaluate apoptosis rates after ART1 overexpression.
Datasets
- The Cancer Genome Atlas (TCGA): A comprehensive repository of genomic, transcriptomic, and clinical data for numerous cancer types.
- Genotypic Tissue Expression (GTEx): Used for normal tissue expression data.
- UCSC Xena Database: A platform for accessing TCGA and GTEx data.
- Human Protein Atlas (HPA): Used for protein expression data and immunohistochemical (IHC) images.
- TISMO Database: For analyzing immune characteristics.
- TIMER Database: For immune cell infiltration analysis.
- CIBERSORT, IPS Algorithm: For immune cell infiltration analysis.
- cBioPortal: For analyzing mutation data.
- SangerBox: For TME biomarker analysis.
- IEU OpenGWAS database: For GWAS data used in co-localization analysis.
No new benchmarks were introduced; the study utilized existing public datasets.
Key Insights and Ideas
- ART1's Dual Role: ART1 expression doesn't have a uniform effect across all cancers. It's associated with poorer prognoses in some (e.g., SKCM, LAML) but favorable prognoses in others (e.g., GBMLGG, BLCA), highlighting its context-dependent nature.
- Immune Microenvironment Modulator: ART1 significantly influences the tumor immune microenvironment (TME), showing correlations with immune checkpoint genes and various immune cell types. This suggests its potential as a target for immunotherapy.
- Gastric Cancer Focus: The study strongly implicates ART1 in gastric cancer progression, with experimental validation showing ART1 overexpression inhibits apoptosis in GC cells, making it a promising target for GC treatment.
- RNA Modification Link: ART1's intricate associations with m1A, m5C, and m6A RNA modification genes suggest a role in regulating gene expression that contributes to tumorigenesis.
- Genetic Overlap: Bayesian co-localization analysis points to potential shared genetic factors between ART1 and digestive tract tumors like STAD and CRC, warranting further investigation into their genetic links.
Key Results
- Differential Expression: ART1 mRNA expression was upregulated in several cancer types (e.g., GBMLGG, BRCA, STAD) and downregulated in others (e.g., GBM, LUAD). Protein expression was elevated in UCEC, STAD, THCA, KIPAN, CESC, and PRAD.
- Prognostic Associations: Elevated ART1 expression was linked to poorer OS in SKCM, LAML, and DLBC, but better OS in GBMLGG, BLCA, and KICH. Similar complex associations were observed for DSS, DFI, and PFI across various cancers.
- Immune Correlations: ART1 showed negative correlations with most immune-related genes but positive correlations with immune checkpoints, suggesting its potential as an immunotherapy target. It also correlated with various immune cell infiltrations, with a notable positive correlation with B cells, CD8+ T cells, and macrophages.
- Gastric Cancer Validation: In vitro experiments confirmed elevated ART1 mRNA and protein levels in GC cell lines and demonstrated that ART1 overexpression significantly reduced apoptosis in HGC-27 cells.
- Genetic Associations: ART1 mutations were found in various cancers, with a notable rate in GBM and adrenocortical carcinoma.
Limitations and Future Work
- Dataset Limitations: The reliance on publicly available datasets means limitations in sample size and potential inherent biases. Larger-scale studies and validation cohorts are needed.
- Mechanistic Elucidation: While the study identified pathways like NF-kB, Foxo, and PI3K-Akt, the precise molecular mechanisms by which ART1 influences the TME and tumorigenesis require further in-depth experimental investigation.
- Clinical Impact Confirmation: Definitive confirmation of whether ART1 directly impacts clinical outcomes through immune-mediated pathways requires additional experimental validation.
- Future Directions: The authors emphasize the need for further in vitro experiments and clinical trials to elucidate ART1's specific molecular mechanisms, its role in tumor progression, and its therapeutic potential, particularly in gastric cancer and immunotherapy.
Summary updated